Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732638 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
A Phase 2 study of Migraine, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,590
- Enrollment target
- 20
- Study locations
NCT03732638 is a Phase 2 study of Migraine that has completed, run by Pfizer. The registered enrollment target is 1,590 participants, above the 343-participant average among 102 other Migraine trials with a reported enrollment target (364% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03732638, a Phase 2 study of Migraine, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,590 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimegepant
Study Locations (20)
California
- Anaheim Clinical Trials - Anaheim
- Axiom Research, LLC - Apple Valley
- Axiom Research, LLC - Colton
- eStudySite - La Mesa
- Synergy San Diego - Lemon Grove
- Collaborative Neuroscience Network, LLC - Long Beach
- Pacific Research Partners, LLC - Oakland
- Artemis Institute for Clinical Research - San Diego
- Optimus Medical Group - San Francisco
- Artemis Institute for Clinical Research - San Marcos
- Neurological Research Institute - Santa Monica
- California Neuroscience Research Medical Group - Sherman Oaks
Arizona
- MDFirst Research-Chandler - Chandler
- MedPharmics, LLC - Phoenix
- Tucson Neuroscience Research - Tucson
Florida
- Riverside Clinical Research - Edgewater
- Galiz Research - Hialeah
- Multi-Specialty Research Associates, Inc. - Lake City
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Connecticut
- Ki Health Partners, LLC, dba New England Institute for Clinical Research - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,590 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732638
The ClinicalTrials.gov registry entry for NCT03732638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,590 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 343-participant average among 102 other Migraine trials with a reported enrollment target (364% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03732638 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT03732638 about?
NCT03732638 is a clinical study titled "Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults". The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
What is the current status of trial NCT03732638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,590 participants. The study started on 2018-11-14. Estimated completion is 2021-02-02.
What conditions does trial NCT03732638 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03732638?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG).
Who is sponsoring clinical trial NCT03732638?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03732638 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.